- Studies demonstrate benefits of liquid biopsy and real-world
data in targeted therapy selection and therapeutic outcomes in
advanced breast cancer
- Interim data from PICI’s RADIOHEAD study using Guardant
Infinity™ platform show correlation between epigenomic biomarkers
and patient response to immunotherapy treatment across more than 13
cancer types
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced the company and its research collaborators
will present data from 16 studies highlighting the role of Guardant
blood tests and real-world data in advancing precision oncology and
cancer screening at the 2024 American Society for Clinical Oncology
(ASCO) Annual Meeting, May 31-June 4 in Chicago.
Featured presentations will share data supporting the utility of
therapy response monitoring with circulating tumor DNA (ctDNA)
using Guardant Infinity and the use of the GuardantINFORM™
clinical-genomic database to characterize drivers and resistance
mechanisms and their association with real-world outcomes in a
variety of solid tumor types. Additional studies will present data
supporting the application of genomic and epigenomic biomarkers in
areas such as minimal residual disease detection and cohort
characterization.
“The robust data we present at ASCO will further demonstrate the
important scientific and clinical developments in cancer care that
are possible using liquid biopsy,” said Helmy Eltoukhy, Guardant
Health chairman and co-CEO. “Several studies will highlight the
tremendous potential of epigenomic analysis using our Guardant
Infinity platform to quantify tumor fraction and characterize
therapy resistance mechanisms in order to improve treatment
response across multiple cancer types.”
Featured presentations include:
- An oral presentation of a study using the Guardant360® liquid
biopsy and exploring racial differences in genomic profiles and
targeted treatment use in ER+ HER2- metastatic breast cancer
(Abstract 1017, Monday, June 3, 11:30 am – 1:00 pm, Hall D1)
- Interim data readout from the collaboration between Guardant
Health and the Parker Institute for Cancer Immunotherapy (PICI) to
identify genomic and epigenomic biomarkers using Guardant Infinity
for quantification of tumor fraction and association with outcomes
from the RADIOHEAD real-world advanced pan-cancer cohort (Abstract
2570, Saturday, June 1, 9:00 am – 12:00 pm, Hall A)
Complete list of Guardant Health and collaborator
presentations at ASCO
Abstract
Title (Hall A unless otherwise
noted)
Product
Saturday, June 1 | 9:00 am – 12:00 pm
2570
Use of a tissue-free epigenomic
circulating tumor DNA (ctDNA) assay for quantification of tumor
fraction (TF) and association with outcomes from RADIOHEAD
real-world advanced pan-cancer cohort
Guardant Infinity
3041
Association of KRAS G12D vs. G12V
circulating tumor DNA variant allele fraction and real-world
overall survival in metastatic non-small cell lung and colorectal
cancers
Guardant Infinity
Saturday, June 1 | 1:30 pm – 4:30 pm
LBA3557
A randomized study evaluating tailoring of
advanced/metastatic colorectal cancer (mCRC) therapy using
circulating tumor DNA (ctDNA): TACT-D
Guardant360 CDx
3519
Candidate molecular alterations associated
with potential resistance in KRAS G12D gastrointestinal cancers
Guardant360 & Guardant360/CDx
3602
Characteristics of patients (pts) with
disease relapse despite absence of molecular residual disease (MRD)
after resection of colorectal oligometastases (CRM): implications
from PRECISION study
Guardant360 & Guardant Reveal™
3545
Characterization of mutational signatures
demonstrating adaptive mutability post anti-EGFR therapy in a
real-world metastatic colorectal cancer cohort
GuardantINFORM
Sunday, June 2 | 9:00 am – 12:00 pm
1037
Molecular profiling of serial liquid
biopsy specimens utilizing cell free DNA (cfDNA) and circulating
tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in
endocrine resistant metastatic breast cancer (MBC)
Guardant Infinity
1043
Evaluating metrics of circulating tumor
DNA response and progression using a high sensitivity
tumor-agnostic assay in metastatic HR+/HER2- breast cancer
receiving endocrine therapy and a CDK4/6-inhibitor
Guardant Infinity
1071
Real-world (RW) elacestrant use patterns
and therapeutic outcomes in patients (pts) with hormone
receptor-positive (HR+)/HER2-negative advanced breast cancer
(aBC)
GuardantINFORM
5069
Dynamic androgen receptor alterations
(ARa) ctDNA profiles and clinical outcomes in metastatic prostate
cancer (mPC)
GuardantINFORM
Monday, June 3 | 9:00 am – 12:00 pm | Hall
A
5592
Serial circulating tumor DNA (ctDNA)
sequencing to monitor response and define acquired resistance to
letrozole/abemaciclib in endometrial cancer (EC)
Guardant Infinity
Monday, June 3 | 11:30 am – 1:00 pm | Hall
D1
1017
Rapid Oral Abstract Session: Racial
differences in genomic profiles and targeted treatment use in ER+
HER2- metastatic breast cancer
Guardant360
Online only
e13097
Co-occurrence of ESR1 and PIK3CA mutations
in HR+/HER2- metastatic breast cancer: Incidence and outcomes with
targeted therapy
Guardant360 & Guardant360 CDx
e12566
Molecular profiling in ABC: Is
complementary testing with tissue and plasma necessary and
clinically relevant?
Guardant360
e13702
Utilization of circulating tumor DNA
(ctDNA) testing by race and ethnicity in more than 135,000
patients
GuardantINFORM
e20088
Use of cell-free tumor DNA in early
detection of lung cancer
Shield™ (next generation)
The full abstracts for Guardant Health and a list of all
abstracts being presented at the meeting can be found at the ASCO
website.
For more information and updates from the meeting, follow
Guardant Health on LinkedIn and X (Twitter) or visit ASCO booth
#28115.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2023, and in
its other reports filed with or furnished to the Securities and
Exchange Commission thereafter. The forward-looking statements in
this press release are based on information available to Guardant
Health as of the date hereof, and Guardant Health disclaims any
obligation to update any forward-looking statements provided to
reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is based,
except as required by law. These forward-looking statements should
not be relied upon as representing Guardant Health’s views as of
any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240530753528/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Michael Weist press@guardanthealth.com +1
317-371-0035
Guardant Health (NASDAQ:GH)
過去 株価チャート
から 5 2024 まで 6 2024
Guardant Health (NASDAQ:GH)
過去 株価チャート
から 6 2023 まで 6 2024